November 12, 2014
Notes: Sun, Gaofeng
Research Support, Non-U.S. Gov’t
Mol Biosyst. 2014 Mar 4;10(3):467-74. doi: 10.1039/c3mb70406h. Epub 2013 Dec 17.
Author Address: Department of Nuclear Medicine, Changhai Hospital of the Second Military Medical University, Room 182., Building 10., 168 Changhai Rd., Shanghai, China200433. email@example.com firstname.lastname@example.org.
Reference Type: Journal Article
Record Number: 4787Author: Sun, H. L., Han, B., Zhai, H. P., Cheng, X. H. and Ma, K.
Title: Rectal NSAIDs for the prevention of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials
Short Title: Rectal NSAIDs for the prevention of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials
Alternate Journal: The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
ISSN: 1479-666X (Print)
Accession Number: 24332479
Abstract: BACKGROUND AND PURPOSE: Acute pancreatitis is the most frequent complication of endoscopic retrograde cholangiopancreatography (ERCP). We conducted a meta-analysis to evaluate the efficacy and safety of rectal nonsteroidal anti-inflammatory drugs (NSAIDs) for the prevention of post-ERCP pancreatitis (PEP). METHODS: PubMed and Embase databases were searched through April 2013. Results are reported as relative risk (RR) or weighted mean difference (WMD) with 95% confidence interval (95% CI). The primary outcome measure was the incidence of PEP. Secondary outcome measures included the severity of PEP and serum amylase level 2 h, 24 h after ERCP. RESULTS: Seven trials containing 1846 patients were eligible. Rectal NSAIDs significantly reduced the incidence of PEP (RR 0.45, 95% CI 0.34-0.61, P < 0.001). The results were maintained in subsequent subgroup analysis. Rectal NSAIDs also was associated with a reduction in the incidence of mild PEP (RR 0.54, 95% CI 0.35-0.83, P = 0.005), moderate to severe PEP (RR 0.39, 95% CI 0.22-0.70, P = 0.002), or serum amylase level 2 h after ERCP (WMD -91.09 IU/L, 95% CI -149.78 to -32.40, P = 0.002). CONCLUSIONS: Rectal NSAIDs reduced the incidence and severity of PEP, as well as serum amylase level 2 h after ERCP.